<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4104">
  <stage>Registered</stage>
  <submitdate>2/01/2013</submitdate>
  <approvaldate>2/01/2013</approvaldate>
  <nctid>NCT01761266</nctid>
  <trial_identification>
    <studytitle>A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma</studytitle>
    <scientifictitle>A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>E7080-G000-304</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatocellular Carcinoma (HCC)</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Non melanoma skin cancer</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Kidney</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Liver</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Lenvatinib
Treatment: drugs - Sorafenib

Active Comparator: Lenvatinib - 

Active Comparator: Sorafenib - 


Treatment: drugs: Lenvatinib
Lenvatinib: 12 mg (or 8 mg) once daily (QD) oral dosing

Treatment: drugs: Sorafenib
Sorafenib: 400 mg twice daily (BID) oral dosing

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Overall survival (OS) - Subjects who are lost to follow-up will be censored at the last date the subject was known to be alive, and subjects who remain alive will be censored at the time of data cutoff.</outcome>
      <timepoint>From date of randomization until date of death from any cause</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-free survival (PFS)</outcome>
      <timepoint>From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurs first</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to progression (TTP)</outcome>
      <timepoint>The time from the date of randomization to the date of first documentation of disease progression</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Objective Response Rate (ORR) - The proportion of subjects who have best overall response of complete response (CR) or partial response (PR).</outcome>
      <timepoint>Date of randomization to the date of disease progression (measured every 8 weeks) or death (whichever occurs first).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Health Related Quality of Life (HRQoL) - HRQoL will be assessed using EORTC QLQ-C30, the HCC-specific questionnaire (HC-18), and a generic instrument EQ-5D-3L.</outcome>
      <timepoint>Baseline Visit, Day 1 of each subsequent cycle, and at the Off-Treatment Visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma PK lenvatinib exposure parameters</outcome>
      <timepoint>Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion Criteria

          1. Subjects must have confirmed diagnosis of unresectable HCC with any of the following
             criteria:

               -  Histologically or cytologically confirmed diagnosis of HCC

               -  Clinically confirmed diagnosis of HCC according to American Association for the
                  Study of Liver Diseases (AASLD) criteria, including cirrhosis of any etiology or
                  with chronic hepatitis B or C infection criteria

          2. At least one measurable target lesion according to mRECIST meeting the following
             criteria:

               -  Hepatic lesion

                    1. The lesion can be accurately measured in at least one dimension as greater
                       than or equal to 1.0 cm (viable tumor for typical; and longest diameter for
                       atypical), and

                    2. The lesion is suitable for repeat measurement

               -  Nonhepatic lesion c. Lymph node (LN) lesion that measures at least one dimension
                  as greater than or equal to 1.5 cm in the short axis, except for porta hepatis LN
                  that measures greater than or equal to 2.0 cm in the short axis d. Non-nodal
                  lesion that measures greater than or equal to 1.0 cm in the longest diameter
                  Lesions previously treated with radiotherapy or locoregional therapy must show
                  radiographic evidence of disease progression to be deemed a target lesion.

          3. Subjects categorized to stage B (not applicable for transarterial chemoembolization
             [TACE]) or stage C based on Barcelona Clinic Liver Cancer (BCLC) staging system

          4. Adequate bone marrow function, defined as:

               -  Absolute neutrophil count (ANC) greater than or equal to 1.5 X 10^9/L

               -  Hemoglobin (Hb) greater than or equal to 8.5 g/dL

               -  Platelet count greater than or equal to 75 X 10^9/L

          5. Adequate liver function, defined as:

               -  Albumin greater than or equal to 2.8 g/dL

               -  Bilirubin less than or equal to 3.0 mg/dL

               -  Aspartate aminotransferase (AST), alkaline phosphatase (ALP), and alanine
                  aminotransferase (ALT) less than or equal to 5 X the upper limit of normal (ULN)

          6. Adequate blood coagulation function, defined as international normalized ratio (INR)
             less than or equal to 2.3

          7. Adequate renal function defined as creatinine clearance greater than 40 mL/min
             calculated per the Cockcroft and Gault formula

          8. Adequate pancreatic function, defined as amylase and lipase less than or equal to 1.5
             X ULN

          9. Adequately controlled blood pressure (BP) with up to 3 antihypertensive agents,
             defined as BP less than or equal to 150/90 mm Hg at Screening and no change in
             antihypertensive therapy within 1 week prior to the Cycle1/Day1

         10. Child-Pugh score A

         11. ECOG-PS 0 or 1

         12. Survival expectation of 12 weeks or longer after starting study drug

         13. Males or females aged at least 18 years (or any age greater than 18 years as
             determined by country legislation) at the time of informed consent

         14. Females must not be lactating or pregnant at Screening or Baseline (as documented by a
             negative beta-human chorionic gonadotropin [B-hCG] test with a minimum sensitivity of
             25 IU/L or equivalent units of B-hCG). A separate baseline assessment is required if a
             negative screening pregnancy test was obtained more than 72 hours before the first
             dose of study drug.

         15. All females will be considered to be of childbearing potential unless they are
             postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age
             group and without other known or suspected cause) or have been sterilized surgically
             (ie, bilateral tubal ligation, total hysterectomy or bilateral oophorectomy, all with
             surgery at least 1 month before dosing)

         16. Females of childbearing potential must not have had unprotected sexual intercourse
             within 30 days before study entry and must agree to use a highly effective method of
             contraception (e.g., total abstinence, an intrauterine device, a double-barrier method
             [such as condom plus diaphragm with spermicide], a contraceptive implant, an oral
             contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout
             the entire study period and for 30 days after study drug discontinuation. If currently
             abstinent, the subject must agree to use a double barrier method as described above if
             she becomes sexually active during the study period or for 30 days after study drug
             discontinuation. Females who are using hormonal contraceptives must have been on a
             stable dose of the same hormonal contraceptive product for at least 4 weeks before
             dosing and must continue to use the same contraceptive during the study and for 30
             days after study drug discontinuation.

         17. Male subjects must have had a successful vasectomy (confirmed azoospermia) or they and
             their female partners must meet the criteria above (i.e., not of childbearing
             potential or practicing highly effective contraception throughout the study period and
             for 30 days after study drug discontinuation). No sperm donation is allowed during the
             study period and for 30 days after study drug discontinuation.

         18. Provide written informed consent

         19. Willing and able to comply with all aspects of the protocol</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion Criteria

          1. Imaging findings for HCC corresponding to any of the following:

               -  HCC with greater than or equal to 50 percent liver occupation

               -  Clear invasion into the bile duct

               -  Portal vein invasion at the main portal branch (Vp4)

          2. Subjects who have received any systemic chemotherapy, including anti-VEGF therapy, or
             any systemic investigational anticancer agents, including lenvatinib, for
             advanced/unresectable HCC. Note: Subjects who have received local hepatic injection
             chemotherapy are eligible.

          3. Subjects who have received any anticancer therapy (including surgery, percutaneous
             ethanol injection, radio frequency ablation, transarterial [chemo] embolization,
             hepatic intra-arterial chemotherapy, biological, immunotherapy, hormonal, or
             radiotherapy) or any blood enhancing treatment (including blood transfusion, blood
             products, or agents that stimulate blood cell production, eg, granulocyte
             colony-stimulating factor [G-CSF]) within 28 days prior to randomization

          4. Subjects who have not recovered from toxicities as a result of prior anticancer
             therapy, except alopecia and infertility. Recovery is defined as less than Grade 2
             severity per Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0).

          5. Significant cardiovascular impairment: history of congestive heart failure greater
             than New York Heart Association (NYHA) Class II, unstable angina, myocardial
             infarction or stroke within 6 months of the first dose of study drug, or cardiac
             arrhythmia requiring medical treatment at Screening

          6. Prolongation of QTc interval to greater than 480 ms

          7. Gastrointestinal malabsorption or any other condition that might affect the absorption
             of lenvatinib in the opinion of the investigator

          8. Bleeding or thrombotic disorders or use of anticoagulants requiring therapeutic INR
             monitoring, eg, warfarin or similar agents. Treatment with low molecular weight
             heparin and factor X inhibitors which do not require INR monitoring is permitted.
             Antiplatelet agents are prohibited throughout the study.

          9. Gastrointestinal bleeding event or active hemoptysis (bright red blood of at least 0.5
             teaspoon) within 28 days prior to randomization

         10. Gastric or esophageal varices that require interventional treatment within 28 days
             prior to randomization. Prophylaxis with pharmacologic therapy (eg, nonselective
             beta-blocker) is permitted.

         11. Active malignancy (except for HCC or definitively treated melanoma in-situ, basal or
             squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix) within the
             past 36 months

         12. Subjects whose only target lesion(s) is in bone will be excluded

         13. Meningeal carcinomatosis

         14. Any history of or current brain or subdural metastases

         15. Subjects having greater than 1+ proteinuria on urine dipstick testing will undergo a
             24-hour urine collection for quantitative assessment of proteinuria. Subjects with a
             urine protein greater than or equal to 1 g/24 hours will be ineligible.

         16. Surgical arterial-portal venous shunt or arterial-venous shunt

         17. Any medical or other condition that in the opinion of the investigator would preclude
             the subject's participation in a clinical study

         18. Known intolerance to lenvatinib or sorafenib (or any of the excipients)

         19. Human immunodeficiency virus (HIV) positive or active infection requiring treatment
             (except for hepatitis virus)

         20. Any history of drug or alcohol dependency or abuse within the prior 6 months

         21. Any subject who cannot be evaluated by either triphasic liver CT or triphasic liver
             MRI because of allergy or other contraindication to both CT and MRI contrast agents

         22. Major surgery within 3 weeks prior to randomization or scheduled for surgery during
             the study

         23. Subject has had a liver transplant</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>14/03/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>954</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>15/12/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC,WA</recruitmentstate>
    <hospital>Facility # 1 - Camperdown</hospital>
    <hospital>Facility # 1 - Wentworthville</hospital>
    <hospital>Facility # 1 - Woolloongabba</hospital>
    <hospital>Facility # 1 - Fitzroy</hospital>
    <hospital>Facility # 1 - Melbourne</hospital>
    <hospital>Facility # 2 - Melbourne</hospital>
    <hospital>Facility # 1 - Nedlands</hospital>
    <postcode> - Camperdown</postcode>
    <postcode> - Wentworthville</postcode>
    <postcode> - Woolloongabba</postcode>
    <postcode> - Fitzroy</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Edegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Liege</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Anhui</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Beijing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Chongqing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Fujian</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Guangdong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Heilongjiang</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Hunan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Jiangsu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Jilin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Liaoning</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Shandong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Shanghai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Shanxi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Tianjin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Zhejiang</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Amiens cedex 1</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Creteil Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier cedex 5</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice Cedex 3</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris cedex 12</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pessac</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rennes cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Vandoeuvre les Nancy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Baden Wuerttemberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Niedersachsen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Nordrhein Westfalen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Rheinland Pfalz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Kowloon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Peta? Tiqwa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Ancona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bari</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Benevento</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Napoli</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Palermo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Aichi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Chiba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Ehime</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Fukuoka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hokkaido</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hyogo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Ishikawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kanagawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Mie</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Nagasaki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Yamaguchi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hiroshima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Okayama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Osaka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Saga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gyeonggi-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gyeonggi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Jeollanam-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Busan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Daegu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Incheon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Pahang</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Sarawak</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Selangor</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kuala Lumpur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Pulau Pinang</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Cebu City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Davao City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Quezon City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Arkhangelsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St. Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Ufa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Cantabria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Badajoz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Girona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Tainan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taoyuan City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Chiang Mai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Chiang Rai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Greater London W12 OHS</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Greater London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Greater Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Merseyside</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Strathclyde</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>West Midlands</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Eisai Limited</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>E7080-G000-304 is a multicenter, randomized, open-label, noninferiority Phase 3 study to
      compare the efficacy and safety of lenvatinib versus sorafenib as a first-line systemic
      treatment in subjects with unresectable Hepatocellular Carcinoma (HCC).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01761266</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>